Journal of Dermatology最新文献

{"title":"Discontinuation Reasons and Drug Survival of Dupilumab in Real-World Adult Atopic Dermatitis Patients in Three Healthcare Facilities in Tokyo and Yokohama (2018–2023)","authors":"Itaru Dekio,&nbsp;Michie Katsuta,&nbsp;Yozo Ishiuji,&nbsp;Yoshimasa Nobeyama,&nbsp;Yumiko Asai,&nbsp;Kanako Ontsuka,&nbsp;Minako Yasumoto,&nbsp;Yoshiyuki Murakami,&nbsp;Akihiko Asahina","doi":"10.1111/1346-8138.17927","DOIUrl":"10.1111/1346-8138.17927","url":null,"abstract":"<div>\u0000 \u0000 <p>Dupilumab, a fully human IgG4 monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling by blocking the shared IL-4α subunit, is the first targeted systemic therapy for moderate-to-severe atopic dermatitis (AD). The drug was introduced in Japan in April 2018, along with other countries around the same time, leading to a dramatic improvement in patients' quality of life. This study aims to provide practical insights into the real-world use of dupilumab to support decision-making in drug selection and patient education. We retrospectively analyzed the clinical course of 314 AD patients who commenced the treatment in a university hospital and two clinics in Tokyo and Yokohama, both in the greater Tokyo metropolitan area, from the launch of the drug until December 2022. Of the 314 patients, 180 (57.3%) remained on the treatment until June 2023, whereas 134 (42.7%) discontinued. Discontinuation reasons included: (i) negative outcomes, such as lack of efficacy or adverse effects, in 46 patients (14.6%) with a median treatment duration of 224 days; (ii) disease remission in 53 patients (16.9%); and (iii) non-disease-related or unknown reasons in 35 patients (11.1%). The drug survival rates at 1, 2, 3, and 4 years after initiation were 72.2%, 56.9%, 49.8%, and 42.3%, respectively. However, when considering only discontinuations due to negative outcomes, these increased to 89.3%, 82.7%, 78.8%, and 75.6%, respectively. To summarize, the drug survival rate in this group was significantly lower than those reported in Western countries. However, when discontinuations due to negative outcomes were considered separately, the rates were comparable. These findings highlight the excellent efficacy of dupilumab, while also suggesting that the doctors and patients in this region may be more inclined to discontinue the treatment despite its success compared with their Western counterparts.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"461-469"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Antimicrobial Peptides in the Pathogenesis of Atopic Dermatitis","authors":"Ge Peng,&nbsp;Alafate Abudouwanli,&nbsp;Quan Sun,&nbsp;Yi Tan,&nbsp;Wanchen Zhao,&nbsp;Mengyao Yang,&nbsp;Shan Wang,&nbsp;Hideoki Ogawa,&nbsp;Ko Okumura,&nbsp;François Niyonsaba","doi":"10.1111/1346-8138.17975","DOIUrl":"10.1111/1346-8138.17975","url":null,"abstract":"<p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by barrier dysfunction, immune dysregulation, and microbial dysbiosis. Recent studies have highlighted the multifaceted roles of antimicrobial peptides (AMPs) both as innate defenders against microbial invasion and as regulators of immune responses and skin barrier homeostasis. This review synthesizes the current knowledge on the dysregulation of AMP expression in AD, the impact of Th2-dominant inflammation on AMP-mediated defense, and the complex relationship between AMP activity and the cutaneous microbiota (particularly in the context of <i>Staphylococcus aureus</i> colonization). We also explore the immunomodulatory and barrier-stabilizing functions of AMPs, emphasizing their dual roles as both protective and potentially pathogenic agents depending on their expression levels and processing. Furthermore, emerging therapeutic strategies that aim to restore AMP function (such as vitamin D signaling, aryl hydrocarbon receptor activation, and synthetic AMPs) are discussed. A deeper understanding of AMP-related mechanisms in AD may offer novel insights for precision-targeted interventions that simultaneously address inflammation, barrier repair, and microbial imbalance.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"372-379"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced Patients","authors":"Toshiki Okazaki,&nbsp;Takehiro Takahashi,&nbsp;Moyuka Wada-Irimada,&nbsp;Mana Sekine,&nbsp;Takuya Takahashi,&nbsp;Tomoko Chiba,&nbsp;Emi Yamazaki,&nbsp;Kosuke Shido,&nbsp;Toshiya Takahashi,&nbsp;Yoshihide Asano","doi":"10.1111/1346-8138.70123","DOIUrl":"10.1111/1346-8138.70123","url":null,"abstract":"<div>\u0000 \u0000 <p>Alopecia areata (AA) is a chronic autoimmune disorder characterized by refractory non-scarring hair loss. Although baricitinib revolutionized AA management, some severe cases remain refractory. Ritlecitinib, an oral selective dual JAK3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor, is a recently approved therapeutic agent for the treatment of severe AA. Although clinical trials have established the benefit of ritlecitinib, real-world data on its outcome and safety, particularly in patients previously exposed to baricitinib, have been still limited. Accordingly, we conducted a single-center, retrospective study of 22 severe AA patients treated with ritlecitinib 50 mg daily for 24 weeks at Tohoku University Hospital, Japan. Nine patients (41%) were JAK inhibitor (JAKi)-naïve, and 13 (59%) had previously received baricitinib for a median of 19 months. JAKi-naïve patients were significantly younger (median 14 vs. 38 years; <i>p</i> = 0.0143) and had shorter current AA episodes (median 20 vs. 68 months; <i>p</i> = 0.0138), compared with the JAKi-experienced group. Baseline SALT score in each group showed similar distribution. At Week 24, all JAKi-naïve patients achieved SALT₅₀ (a decrease of at least 50% from baseline in the SALT score); 7/9 (78%) attained SALT ≤ 20 and SALT₇₅ (a decrease of at least 75% from baseline in the SALT score). In contrast, among JAKi-experienced patients, only 3/13 (23%) achieved SALT₅₀, and 1/13 (8%) reached SALT₇₅, whereas a reduction in SALT score from baseline was observed in 7 of 13 (54%). Importantly, no patients in both groups experienced SALT worsening or treatment-related adverse events. Our findings highlighted that ritlecitinib is highly effective especially in adolescent JAKi-naïve AA, and although the clinical effect may be limited in JAKi-experienced patients, switching from baricitinib to ritlecitinib remains one of the viable options due to its low risk of disease exacerbation.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"470-477"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysbiosis in the Pathogenesis of Atopic Dermatitis","authors":"Hiroki Okamoto,&nbsp;Yuumi Nakamura","doi":"10.1111/1346-8138.70191","DOIUrl":"10.1111/1346-8138.70191","url":null,"abstract":"<p>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction and immune dysregulation. Recent research highlights cutaneous dysbiosis as a critical factor in its pathogenesis. In this review, we summarize the interplay between the skin microbiota and host immunity, contrasting the homeostatic state with the dysbiosis in AD. In healthy skin, resident microbial communities, including coagulase-negative staphylococci and <i>Cutibacterium acnes</i>, contribute to immune education and pathogen defense. In AD, this equilibrium is disrupted, leading to a state of functional dysbiosis characterized not only by reduced microbial diversity and the predominance of <i>Staphylococcus aureus</i> but also by the loss of protective commensal functions. The virulence of <i>S. aureus</i> is pivotal, with its accessory gene regulator (Agr) quorum-sensing system driving the expression of toxins like δ-toxin, which exacerbates type 2 inflammation and barrier defects. Crucially, colonization in early life with <i>S. aureus</i> strains possessing a functional Agr system is strongly associated with an increased risk of subsequent AD development. This understanding has prompted a paradigm shift in therapeutic strategies. Recognizing the limitations of traditional broad-spectrum antimicrobials, which can worsen dysbiosis, novel approaches now focus on restoring microbial balance. These include bacteriotherapy using beneficial commensal strains to competitively inhibit <i>S. aureus</i>, quorum-quenching agents, and preventive skincare interventions initiated in infancy to foster a healthy microbiome. A deeper comprehension of these host-microbe and microbe-microbe interactions is essential for optimizing these promising microbiome-targeted therapies for AD.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"388-398"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146260549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Pathogenesis of Atopic Dermatitis-Trends for the Future","authors":"Norito Katoh","doi":"10.1111/1346-8138.70164","DOIUrl":"10.1111/1346-8138.70164","url":null,"abstract":"<p>Atopic dermatitis (AD) was formerly regarded as a chronic inflammatory skin disease with an ambiguous pathogenesis. However, recent advances in science and technology have elucidated the complex pathogenesis of AD. The primary findings indicate that two abnormalities, “skin barrier dysfunction” typified by filaggrin gene mutations, and “type 2 inflammation” centered on IL-4 and IL-13, interact to form the pathogenesis of AD. Sakai introduces the latest findings on the vicious cycle between type 2 inflammation and stratum corneum lipid abnormalities and the utility of noninvasive assessment of stratum corneum ceramides as biomarkers of disease activity, therapeutic response, and relapse risk.</p><p>It has long been known that <i>Staphylococcus aureus</i> is frequently detected in AD lesions and has been considered one of the exacerbating factors. Okamoto and Matsuoka provide the current knowledge on functional dysbiosis and the accessory gene regulator quorum-sensing system in the pathogenesis of AD, and discuss the future therapeutic applications. Antimicrobial peptides work as regulators of immune responses and skin barrier homeostasis in addition to innate defenders against microbial invasion including bacteria, fungus, and virus. Peng and Niyonsaba et al. describe the recent findings about antimicrobial peptides in the pathogenesis of AD and emerging therapeutic strategies.</p><p>Advances in research into the pathogenesis of AD have brought many new therapeutic options to patients who were previously unable to induce remission. Given the heterogeneity of AD, it is hypothesized that the involvement of each pathogenic factor is subject to variation among individual patients. It is, therefore, important to understand the mechanisms of action of each treatment for AD and to select the optimal therapy for individual patients in daily clinical practice. I hope that this special issue will help readers understand future trends in the pathogenesis of AD.</p><p>Norito Katoh has received honoraria as a speaker/consultant for Sanofi, Maruho, Abbvie, Ely-Lilly Japan, Taiho Pharmaceutical, Pfizer, Mitsubishi Tanabe Pharma, Jansen Pharma, Kyowa Kirin, Celgene Japan, Torii Pharmaceutical, Novartis Pharma, and Otsuka Pharmaceutical and has received grants as an investigator from Mitsubishi Tanabe Pharma, Torii Pharmaceutical, Maruho, Sun Pharma, Boehringer Ingelheim Japan, and Leo Pharma.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146115519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaphylaxis to Total Parenteral Nutrition Components Diagnosed by Skin Tests","authors":"Tadashi Hayakawa,&nbsp;Toshihiko Komai,&nbsp;Takayuki Yotsuyanagi,&nbsp;Toshiaki Shimizu,&nbsp;Keita Murakami,&nbsp;Ken Kurokawa,&nbsp;Nobumi Suzuki,&nbsp;Mitsuhiro Fujishiro,&nbsp;Keishi Fujio","doi":"10.1111/1346-8138.70127","DOIUrl":"10.1111/1346-8138.70127","url":null,"abstract":"<div>\u0000 \u0000 <p>Parenteral nutrition (PN) is a critical intervention for patients unable to tolerate enteral nutrition. Commercially available multi-chamber PN formulations are widely used due to their safety and cost-effectiveness. However, hypersensitivity reactions (HSRs), including anaphylaxis, must be carefully considered. Here, we report on a 38-year-old female with intestinal obstruction due to peritoneal dissemination of colon cancer who developed anaphylaxis to a multi-chamber PN formulation. Skin prick and intradermal tests identified the specific chamber as the causative component. PN-related HSRs are rare, but can severely impact nutritional management. Identifying specific allergens is crucial for avoiding unnecessary PN discontinuation. This case highlights the importance of incorporating allergy testing into the management of multi-chamber PN, allowing safe continuation of nutrition and guiding individualized strategies for patients at risk of hypersensitivity.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"514-517"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-Year Real-World Effectiveness of Deucravacitinib 6 mg in Psoriasis: A Single-Center Analysis Stratified by Body Mass Index or Age in a Japanese Cohort","authors":"Yuriko Okabe,&nbsp;Teppei Hagino,&nbsp;Yohei Takahashi,&nbsp;Hidehisa Saeki,&nbsp;Eita Fujimoto,&nbsp;Naoko Kanda","doi":"10.1111/1346-8138.70137","DOIUrl":"10.1111/1346-8138.70137","url":null,"abstract":"<div>\u0000 \u0000 <p>Real-world data are limited on 2 year effectiveness of tyrosine kinase 2 inhibitor deucravacitinib for psoriasis, especially that stratified by body mass index (BMI) or age. This study is aimed to evaluate 104 week effectiveness of deucravacitinib in patients with psoriasis, stratified by BMI (&lt; 25 versus ≥ 25 kg/m²) or age (&lt; 65 versus ≥ 65 years). We included 127 patients with moderate-to-severe psoriasis who received deucravacitinib 6 mg once daily. Psoriasis area and severity index (PASI) decreased throughout 104 weeks in whole patients. In between-group comparisons, mean percent reduction of PASI did not significantly differ at any time point in either BMI or age stratification. The amount of decreasing PASI and achievement rates of PASI 75, 90, and absolute PASI ≤ 2 through week 16 to 68 were slightly higher in BMI &lt; 25 than in BMI ≥ 25, thereafter inverted order. The achievement rates of PASI 100 or absolute PASI ≤ 1 were higher in BMI &lt; 25 throughout 104 weeks; week 104 PASI 100 or absolute PASI ≤ 1 rates were 16.7% or 54.2% in BMI &lt; 25 while 0% or 40% in BMI ≥ 25, respectively. Percent reduction of PASI and achievement rates of PASI 75 and 90 were slightly higher in age ≥ 65 years than in age &lt; 65 years by week 52, thereafter inverted order. Week 104 achievement rates of PASI 100 or absolute PASI ≤ 1 were 28.6% or 57.1% in age &lt; 65 years while 0% or 46.7% in age ≥ 65 years, respectively. Deucravacitinib reduced PASI throughout 104 weeks in whole patients. Patients with BMI &lt; 25 or age ≥ 65 years might show slightly higher response to deucravacitinib at early time points around 1 year compared to slightly higher response at later time points in those with BMI ≥ 25 or age &lt; 65 years. Patients with BMI ≥ 25 or age ≥ 65 years might have difficulty in keeping PASI 100 through week 104.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"496-505"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns and Healthcare Utilization on Pediatric Atopic Dermatitis With Allergic Comorbidities: A Japanese Claims-Based Study","authors":"Masaki Futamura,&nbsp;Yumi Kang,&nbsp;Ambrish Singh,&nbsp;Junichi Danjo,&nbsp;Takashi Matsuo,&nbsp;Hitoe Torisu-Itakura,&nbsp;Mizuho Nagao","doi":"10.1111/1346-8138.70102","DOIUrl":"10.1111/1346-8138.70102","url":null,"abstract":"<p>Atopic dermatitis (AD) is a chronic, itchy skin disease that often begins in infancy and may persist into adulthood. The high co-occurrence of allergic comorbidities (ACMs; asthma, food allergy, and allergic rhinitis) makes it a growing public health concern. However, real-world data on treatment patterns and the economic burden of AD in children remain sparse. This retrospective observational study aimed to assess the clinical profiles of pediatric patients with AD using data from the JMDC Claims database. Children aged 0–6 years diagnosed with AD between January 2018 and September 2023 were included. A total of 244 316 children with AD (mean age: 3.1 years; 51.3% male) were included. Of these, 17.7% had AD-only, and 82.3% had AD with ACM. Allergic rhinitis was the most prevalent ACM. Topical corticosteroids were the most prescribed treatment, with 94.0% of patients with ACMs and 85.5% of those with AD-only receiving them. Potent corticosteroids were more frequently used in the AD with ACM group. Systemic steroids (31.5% vs. 4.8%) and antihistamines (95.5% vs. 56.1%) were used more often in the AD with ACMs group than in the AD-only group. Patients in the AD with ACM versus AD-only group had more outpatient visits (11.1/year vs. 6.5/year) and comparable hospitalization frequency, but shorter hospital stays (2.4 vs. 7.7 days per year). Median annual healthcare costs were substantially higher in the AD with ACM group compared to the AD-only group (139 391 Yen vs. 98 646 Yen), with costs increasing as the number of ACMs increased. Notably, 84.7% of patients with three ACMs incurred annual healthcare costs exceeding 100 000 Yen. These findings highlighted the increased clinical and economic burden associated with the increasing number of ACMs in children with AD, emphasizing the need for more intensive treatment and healthcare resources.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"437-446"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment Following Switch From Topical Corticosteroids for Trunk and Extremity Rash in Atopic Dermatitis","authors":"Masatoshi Abe,&nbsp;Atsuyuki Igarashi,&nbsp;Hiroyuki Kitajima,&nbsp;Hiroyuki Toyama,&nbsp;Kenji Kabashima,&nbsp;Hidehisa Saeki","doi":"10.1111/1346-8138.17915","DOIUrl":"10.1111/1346-8138.17915","url":null,"abstract":"<p>Atopic dermatitis (AD) is a chronic inflammatory disease characterized by recurrent remissions and relapses. Topical anti-inflammatory steroids are commonly used for treatment, but their long-term use poses concerns because of potential side effects. Delgocitinib ointment, a Janus kinase inhibitor, has demonstrated efficacy in several clinical studies and is expected to be a viable alternative to topical corticosteroids (TCS). To evaluate the real-world safety and efficacy of delgocitinib in Japanese patients, we assessed the benefits of switching from TCS to delgocitinib ointment in AD patients with rashes on the trunk and extremities. Overall, data from 93 patients (mean age: 35 years) were analyzed. Patients switched from TCS to delgocitinib ointment and were followed for up to 12 weeks. Treatment outcomes were assessed using the treatment Satisfaction questionnaire for medication-9 (TSQM-9), Eczema Area and Severity Index (EASI), modified EASI (mEASI), Numerical Rating Scale (NRS) for itching, Atopic Dermatitis Control Tool (ADCT), and Patient Preference Questionnaire (PPQ). During the observation period, TSQM-9 scores were significantly improved (effectiveness 68.3 to 72.9, <i>p</i> &lt; 0.05; global satisfaction 61.7 to 67.9, <i>p</i> &lt; 0.01). Additionally, mEASI (8.82 to 6.92, <i>p</i> &lt; 0.05), EASI (9.60 to 7.43, <i>p</i> &lt; 0.001), NRS (5.6 to 4.5, <i>p</i> &lt; 0.001), and ADCT (8.8 to 5.5, <i>p</i> &lt; 0.001) scores were decreased during treatment. Moreover, local side effects were improved, with a &gt; 20% reduction in the severity of skin atrophy and telangiectasia. Approximately 72% of patients reported that “the study drug is more effective” using the PPQ. Taken together, our study demonstrates that delgocitinib ointment is an effective treatment option for AD patients with rashes of the trunk and extremities, as well as for those concerned about the potential side effects of TCS.</p><p><b>Trial Registration:</b> The study was registered at the Japan Registry of Clinical Trials (jRCTs031230102).</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 3","pages":"410-420"},"PeriodicalIF":2.7,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pigmentary Disorders: Elucidation of Pathogenesis for Recovery of Health and Wellness","authors":"Naoki Oiso","doi":"10.1111/1346-8138.70157","DOIUrl":"10.1111/1346-8138.70157","url":null,"abstract":"<p>Okamura and Suzuki focus on genetic pigmentary disorders of hypopigmented disorders, hyperpigmented disorders, and RASopathies. They summarize recent novel findings in relationship between molecular mechanism and clinical manifestation. Okamura and Suzuki indicate that increasing genetic knowledge allows development of precision medicine approaches to personalized management strategies.</p><p>Inoue summarizes current knowledge on the factors leading to the onset and progression of vitiligo. Inoue integrates current facts about crosstalk between immune and non-immune cells. Inoue presents the concept of “unstable equilibrium” between destructive and regulatory forces in the seemingly healthy non-lesional skin in vitiligo patients. The concept might shift therapeutic strategies from treatment of vitiligo as a localized disorder to management of vitiligo as a systemic disease.</p><p>Kuroda, Yang and Katayama have investigated CL and CIV. They are currently revealing controversial processes in CL and CIV. Repigmentation and subsequent recovery occurs after eliminating the causative chemical in individuals with CL. A process of persistence, expansion, and/or appearance of other lesions occurs even after removing the causative chemical in persons with CIV. Kuroda, Yang &amp; Katayama comment that numerous aspects of CIV pathogenesis remain to be clarified and that further research is required to facilitate the development of effective therapeutic interventions.</p><p>This special issue summarizes novel findings and would contribute to novel approaches for recovery of health and wellness in individuals with pigmentary disorders.</p><p>The author has nothing to report.</p><p>Naoki Oiso is an Editorial Board member of Journal of Dermatology and a co-author of this article. To minimize bias, Naoki Oiso was excluded from all editorial decision-making related to the acceptance of this article for publication.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 2","pages":"167-168"},"PeriodicalIF":2.7,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70157","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}